Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Vanier Canada Graduate Scholarships - Doctoral

McMaster University

$50,000.00

Endogenous Nonionic Unsaturated Monoethanolamide Lipids as a Posterior Eye Drug Delivery System

FY 2012-13

Summary
Retinoblastoma is a cancer of the eye that often affects children by the age of 3. Typical treatments currently include removal of the eye or chemotherapy. While novel therapeutics have been developed that may act as chemo-preventative agents and reduce the incidence of this cancer in susceptible children, the delivery of these drugs to the back of the eye remains an engineering challenge. To accommodate this, both a traditional and a novel drug delivery system are being explored. Due to the nature of the disease, an injection into the eye is undesirable, so sclera delivery methods using both traditional fibrin gels and also lipids which create a gel-like phase are being explored. These materials will be loaded with the required therapeutics and tailored such that the release of the drugs from the materials effectively maintains a therapeutic dose at the retinal site of interest to prevent the cancer formation for the desired length of time. After confirming the release kinetics by in vitro methods, this formulation would then undergo animal testing to confirm the results in vivo and determine any additional benefits or potential side effects. It is also believed that these novel lipids can be injected and will gel in situ, which while not suitable for a retinoblastoma application, will be explored for other posterior eye drug delivery applications such as age-related macular degeneration.
Program
Vanier Canada Graduate Scholarships - Doctoral
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
405754-2011
Name nom
Lasowski, Frances
Department département
Biomedical Engineering, School of
Organization id
27
Institution établissement
McMaster University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2012
Competition year année de concours
2011
Award amount
50000
Program id
VCGS
Program name en
Vanier Canada Graduate Scholarships - Doctoral
Program name fr
Bourses d'études supérieures du Canada Vanier - Doctorat
Group en
Training programs
Group fr
Programmes de bourse
Committee code
1082
Committee name en
Vanier Selection Committee
Committee name fr
Comité de sélection Vanier
Area of application code
9999
Area of application group en
Not available
Area of application group fr
Non disponible
Area of application en
Not available
Area of application fr
Non disponible
Research subject code
1900
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical engineering
Research subject fr
Génie biomédical
Partie
0
Application title
Endogenous Nonionic Unsaturated Monoethanolamide Lipids as a Posterior Eye Drug Delivery System
Keyword
NSERC
Application summary
Retinoblastoma is a cancer of the eye that often affects children by the age of 3. Typical treatments currently include removal of the eye or chemotherapy. While novel therapeutics have been developed that may act as chemo-preventative agents and reduce the incidence of this cancer in susceptible children, the delivery of these drugs to the back of the eye remains an engineering challenge. To accommodate this, both a traditional and a novel drug delivery system are being explored. Due to the nature of the disease, an injection into the eye is undesirable, so sclera delivery methods using both traditional fibrin gels and also lipids which create a gel-like phase are being explored. These materials will be loaded with the required therapeutics and tailored such that the release of the drugs from the materials effectively maintains a therapeutic dose at the retinal site of interest to prevent the cancer formation for the desired length of time. After confirming the release kinetics by in vitro methods, this formulation would then undergo animal testing to confirm the results in vivo and determine any additional benefits or potential side effects. It is also believed that these novel lipids can be injected and will gel in situ, which while not suitable for a retinoblastoma application, will be explored for other posterior eye drug delivery applications such as age-related macular degeneration.